- Pace Life Sciences is expanding its Salem, NH, and Oakdale, MN facilities to enhance sterile fill-finish and analytical service capabilities.
- The expansion projects aim to accelerate clinical trial materials production and support growing demand in biologics, gene therapies, and novel molecules.

Pace Life Sciences, a U.S.-based contract research, development, and manufacturing organisation (CRDMO), has announced substantial expansion plans for its facilities in Salem, New Hampshire, and Oakdale, Minnesota. The upgrades are designed to bolster capabilities in sterile fill-finish and analytical services to better serve clients developing biologics, gene therapies, and novel therapeutic molecules.
The Oakdale, MN facility, which received a 2024 grant from the Minnesota Department of Employment and Economic Development (DEED), will gain an additional 8,000 square feet. The expansion is expected to create over 50 new jobs and will enhance the site’s capacity for testing drugs entering commercial production. Key improvements include a dedicated RNase-free environment and expanded cell-based assay support. This site is one of the fastest-growing in the company’s network, catering to both widely distributed drugs and rare disease therapies.
In Salem, NH, the upgraded facility will be classified as a Centre of Excellence (CoE) for Sterile Fill-Finish processing. Enhancements include the addition of an isolated vial filling line, offering the highest sterility assurance and compliance with EU Annex 1. This investment will support cGMP manufacturing for vaccines, gene therapies, antibodies, and protein-based therapeutics. “The addition of our isolated vial filling line … gives us a state-of-the-art capability for manufacturing clinical supplies,” said Frank Tagliaferri, Chief Science Officer of Pace Life Sciences.
The expansions build on the company’s 2024 milestones, which include the acquisition of locations in Research Triangle Park, NC, and Lebanon, NJ, broadening expertise in container closure integrity testing (CCIT). “We are continuously looking for ways to improve and invest in our services,” noted Dawn Von Rohr, President of Pace Life Sciences.